Colorado Pharma Co. investor sues for stock split and subsidy

By Jeff Montgomery (March 4, 2022, 4:09 PM EST) – Biopharmaceutical company Aytu Biopharma Inc. has been the subject of a spin-off shareholder lawsuit accusing its CEO and four directors of wrongfully attributing more than $10 million in stock while ignoring new limits on incentive awards resulting from a stock split.

Shareholder Paul John M. Paguia filed the suit on behalf of the Colorado-based company and its investors on Thursday, alleging chief executive Gary Cantrell and four directors handed themselves 9% of the company without approval. appropriate board or shareholder disclosure.

The allegations were significant enough, according to Paguia’s lawsuit, to cause the resignations in May 2021 of two…

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of lawsuits, etc.)
  • Access to attached documents such as briefs, motions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and more!


About Jason Norton

Check Also

Low stock price triggers Nasdaq delisting warning for AlerisLife

AlerisLife (Nasdaq: ALR) needs to raise its stock price or face possible delisting from the …